In late 2014 MedPAC* published a critical analysis on the widespread prescribing of opioid (narcotic) drugs for Medicare beneficiaries. This analysis excluded the use of opioids for cancer and hospice patients (those with terminal illnesses). The findings of the MedPAC analysis, as well as the HHS Office of the Inspector General (2015) were striking:
- More than 30% of Medicare Part D enrollees fill an opioid narcotic prescription each year for purposes other than relief of cancer pain or another terminal illness;
- The highest prevalence of narcotic prescription use among Part D enrollees was concentrated in 12 states: Oklahoma, Arkansas, Louisiana, Alabama, Mississippi, Georgia, South Carolina, North Carolina, Tennessee, Kentucky, West Virginia, and Alaska;
- In 2012 more than 700,000 hospitalizations could be traced to the improper abuse of opioids;
- Between 2006 and 2014 spending for commonly abused opioids grew from $1.5 billion to $3.9 billion among Part D claimants, an increase of 156%.
- Growth in spending for the opioids outpaced overall drug spending in this period by 156% to 136%. Critically, the growth in Part D opioid utilization doubled the growth rate of Part D beneficiaries (68%). This fact strongly points to a sharp increase in opioid utilization for the average beneficiary who may fill these prescriptions.
- Approximately 1/3 of opioid users obtained prescriptions from 4 or more prescribers and the users filled opioid prescriptions at 3 or more pharmacies in a single year. These utilization patterns were strongly suggestive of abuse and/or diversion (misuse of drugs away from legal and medically necessary purposes to uses that are illegal and lack medical necessity).
In response to the above patterns of opioid abuse that have come to light, Congress sternly directed the Department of Health and Human Services to do much more. Congress specifically mandated an improvement in reporting opportunities to mitigate opioid prescription drug abuse and dependency.
Among the Congressionally-mandated measures were:
- Strengthening of surveillance;
- Improve prescription drug abuse prevention programs;
- Enhance coordination among federal programs charged with addressing these issues;
- Collaboration with insurers and pharmacy benefit managers to enhance surveillance, reporting, and mitigation efforts.
Pharmaceutical fraud results in substantial loss to the public fisc, and overutilization of opioid drugs has, and will continue to contribute to this loss.